Cargando…

Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases

The outbreak of the coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 that has created huge trepidation worldwide, has a mortality rate of 0.5% to 1% and is growing incessantly. There are currently no therapies and/or vaccines that may help abate this...

Descripción completa

Detalles Bibliográficos
Autores principales: Ratha, Sachitra K., Renuka, Nirmal, Rawat, Ismail, Bux, Faizal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680017/
https://www.ncbi.nlm.nih.gov/pubmed/33412367
http://dx.doi.org/10.1016/j.nut.2020.111089
_version_ 1783612377344770048
author Ratha, Sachitra K.
Renuka, Nirmal
Rawat, Ismail
Bux, Faizal
author_facet Ratha, Sachitra K.
Renuka, Nirmal
Rawat, Ismail
Bux, Faizal
author_sort Ratha, Sachitra K.
collection PubMed
description The outbreak of the coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 that has created huge trepidation worldwide, has a mortality rate of 0.5% to 1% and is growing incessantly. There are currently no therapies and/or vaccines that may help abate this viral disease, but the use of masks and social distancing can limit the spread. Boosting immunity has been a simple way to resist viral infection and limit fatalities. In this context, the use of nutraceuticals appears to be a potential panacea. The ability of algae-based nutraceuticals, mainly Spirulina, to boost immunity against viral diseases has already been reported clinically. Spirulina-based nutraceuticals boost the adaptive and innate immunity, and bioactive compounds, such as angiotensin-converting enzyme (ACE) inhibitor peptides, phycobiliproteins, sulfated polysaccharides, and calcium-Spirulan, can serve as antiviral agents. The presence of these molecules indicates its potential role in resisting infection and COVID-19 disease progression. This review focuses on the potential role of algal nutraceuticals as immune boosters to combat the human coronavirus and other viral diseases. The potential use of Spirulina-based nutraceuticals for combating COVID-19, its mechanism, and future directions have also been discussed.
format Online
Article
Text
id pubmed-7680017
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-76800172020-11-23 Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases Ratha, Sachitra K. Renuka, Nirmal Rawat, Ismail Bux, Faizal Nutrition Review The outbreak of the coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 that has created huge trepidation worldwide, has a mortality rate of 0.5% to 1% and is growing incessantly. There are currently no therapies and/or vaccines that may help abate this viral disease, but the use of masks and social distancing can limit the spread. Boosting immunity has been a simple way to resist viral infection and limit fatalities. In this context, the use of nutraceuticals appears to be a potential panacea. The ability of algae-based nutraceuticals, mainly Spirulina, to boost immunity against viral diseases has already been reported clinically. Spirulina-based nutraceuticals boost the adaptive and innate immunity, and bioactive compounds, such as angiotensin-converting enzyme (ACE) inhibitor peptides, phycobiliproteins, sulfated polysaccharides, and calcium-Spirulan, can serve as antiviral agents. The presence of these molecules indicates its potential role in resisting infection and COVID-19 disease progression. This review focuses on the potential role of algal nutraceuticals as immune boosters to combat the human coronavirus and other viral diseases. The potential use of Spirulina-based nutraceuticals for combating COVID-19, its mechanism, and future directions have also been discussed. Elsevier Inc. 2021-03 2020-11-21 /pmc/articles/PMC7680017/ /pubmed/33412367 http://dx.doi.org/10.1016/j.nut.2020.111089 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
Ratha, Sachitra K.
Renuka, Nirmal
Rawat, Ismail
Bux, Faizal
Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases
title Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases
title_full Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases
title_fullStr Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases
title_full_unstemmed Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases
title_short Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases
title_sort prospective options of algae-derived nutraceuticals as supplements to combat covid-19 and human coronavirus diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680017/
https://www.ncbi.nlm.nih.gov/pubmed/33412367
http://dx.doi.org/10.1016/j.nut.2020.111089
work_keys_str_mv AT rathasachitrak prospectiveoptionsofalgaederivednutraceuticalsassupplementstocombatcovid19andhumancoronavirusdiseases
AT renukanirmal prospectiveoptionsofalgaederivednutraceuticalsassupplementstocombatcovid19andhumancoronavirusdiseases
AT rawatismail prospectiveoptionsofalgaederivednutraceuticalsassupplementstocombatcovid19andhumancoronavirusdiseases
AT buxfaizal prospectiveoptionsofalgaederivednutraceuticalsassupplementstocombatcovid19andhumancoronavirusdiseases